Mobile

Résultat de votre recherche par promoteur : Bayer HealthCare AG/Bayer Schering Pharma AG

Femme Max 99 ans
Bayer HealthCare AG/Bayer Schering Pharma AG MAJ Il y a 4 ans

Multicenter, open-label, randomized, uncontrolled study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy young female volunteers over a period of 3 treatment cycles The primary objective of the study is to evaluate the inhibition of ovulation in treatment cycles 2 and 3 after administration of two different patches containing EE and GSD for 3 treatment cycles.

  • Pays Aucun
  • Organes Aucun
  • Spécialités Aucune
Essai clos aux inclusions
Plus d'informations